Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial - PubMed
5 hours ago
- #breast cancer
- #CDK4/6 inhibitor
- #clinical trial
- Study evaluates dalpiciclib plus chidamide in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor failure.
- Phase Ib trial identifies maximum tolerated dose (MTD) as group C (dalpiciclib 100 mg/d, chidamide 25 mg BIW).
- Common grade 3-4 adverse events include neutropenia (100%), leukopenia (64%), and thrombocytopenia (36%).
- Objective response rate (ORR) is 9.1% overall and 16.7% at MTD.
- Median progression-free survival (PFS) is 5.8 months overall and 12.3 months at MTD.
- Patients with PIK3CA mutations have shorter median PFS compared to wild type.
- Combination therapy shows manageable safety and preliminary antitumor activity post-CDK4/6 inhibitor failure.